INT230-6

About Intensity Therapeutics

Intensity Therapeutics is on a mission to transform solid tumor treatment by combining direct tumor killing with in situ vaccination. Its core achievement is the DfuseRx℠ platform, which enhances drug dispersion and penetration within tumors to induce immunogenic cell death and a systemic T-cell response. The company's strategy centers on advancing its lead asset, INT230-6, through late-stage trials in breast cancer and sarcomas, with the goal of validating its platform and creating a new class of cancer immunotherapy. As a public company, it faces the critical challenge of generating pivotal clinical data to support regulatory approval and commercial adoption.

About Intensity Therapeutics

Intensity Therapeutics is on a mission to transform solid tumor treatment by combining direct tumor killing with in situ vaccination. Its core achievement is the DfuseRx℠ platform, which enhances drug dispersion and penetration within tumors to induce immunogenic cell death and a systemic T-cell response. The company's strategy centers on advancing its lead asset, INT230-6, through late-stage trials in breast cancer and sarcomas, with the goal of validating its platform and creating a new class of cancer immunotherapy. As a public company, it faces the critical challenge of generating pivotal clinical data to support regulatory approval and commercial adoption.

About Intensity Therapeutics

Intensity Therapeutics is on a mission to transform solid tumor treatment by combining direct tumor killing with in situ vaccination. Its core achievement is the DfuseRx℠ platform, which enhances drug dispersion and penetration within tumors to induce immunogenic cell death and a systemic T-cell response. The company's strategy centers on advancing its lead asset, INT230-6, through late-stage trials in breast cancer and sarcomas, with the goal of validating its platform and creating a new class of cancer immunotherapy. As a public company, it faces the critical challenge of generating pivotal clinical data to support regulatory approval and commercial adoption.

About Intensity Therapeutics

Intensity Therapeutics is on a mission to transform solid tumor treatment by combining direct tumor killing with in situ vaccination. Its core achievement is the DfuseRx℠ platform, which enhances drug dispersion and penetration within tumors to induce immunogenic cell death and a systemic T-cell response. The company's strategy centers on advancing its lead asset, INT230-6, through late-stage trials in breast cancer and sarcomas, with the goal of validating its platform and creating a new class of cancer immunotherapy. As a public company, it faces the critical challenge of generating pivotal clinical data to support regulatory approval and commercial adoption.

Therapeutic Areas